Ando N, Ozawa S, Kitagawa Y, Takeuchi H, Kitajima M
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Nihon Geka Gakkai Zasshi. 1997 Sep;98(9):767-72.
The standard modality of the treatment for the patients with T4 esophageal cancer, whose prognosis still remains quite poor, is not established yet. Salvage surgery for the T4 esophageal cancer following downstaging by neoadjuvant chemo-radiotherapy has become to be available. During the period from 1992 to 96, 30 patients with the suspected T4 esophageal cancer underwent chemoradiotherapy, which consisted of two courses of CDDP/5-FU with-sequential or concurrent 50-60Gy radiotherapy. Among them eleven patients became to be resectable by means of thoracotomy and laparotomy and pathological CRs were obtained in either primary lesions or lymph nodes. The longest survival term following surgery is 36 months. Three patients died of cancer recurrence including the organ metastasis and one died from pyothorax without cancer due to severe immunosuppression attributable to chemoradiation. Our results warrants further studies of neoadjuvant chemoradiotherapy for the patients with T4 esophageal cancer.
T4期食管癌患者的标准治疗方式尚未确立,其预后仍然很差。新辅助放化疗使肿瘤降期后对T4期食管癌患者进行挽救性手术已成为可能。1992年至1996年期间,30例疑似T4期食管癌患者接受了放化疗,方案为两疗程顺铂/氟尿嘧啶,序贯或同步进行50 - 60Gy放疗。其中11例患者通过开胸和开腹手术得以切除肿瘤,原发灶或淋巴结均获得了病理完全缓解。术后最长生存期为36个月。3例患者死于癌症复发,包括器官转移,1例因放化疗导致严重免疫抑制,死于无癌性脓胸。我们的结果表明有必要对T4期食管癌患者的新辅助放化疗进行进一步研究。